ArticleBMC cancer2011
Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas.
Article in BMC cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis.Diagnostic pathology · 2015Pooled it
- Correlation of human epidermal growth factor receptor protein expression and colorectal cancer.World journal of gastroenterology · 2015Pooled it
- HER-2 overexpression and survival in colorectal cancer: a meta-analysis.Journal of Zhejiang University. Science. B · 2014Pooled it
- Prognostic impact of p53 and HER2 immunohistochemistry profiles in colorectal carcinoma.Pathology oncology research : POR · 2026Article
- Assessment of HER2/Neu Expression in Colorectal Carcinomas and Its Correlation With Tumor Stage and Histopathology.Cureus · 2025Article
- Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future.ESMO gastrointestinal oncology · 2024Review
- Quantitative parameters of dual-layer spectral detector computed tomography for evaluating Ki-67 and human epidermal growth factor receptor 2 expression in colorectal adenocarcinoma.Quantitative imaging in medicine and surgery · 2024Article
- Article
- Unraveling the role of disulfidptosis-related LncRNAs in colon cancer: a prognostic indicator for immunotherapy response, chemotherapy sensitivity, and insights into cell death mechanisms.Frontiers in molecular biosciences · 2023Article
- EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer.Scientific reports · 2022Article
- Polyisoprenylated Cysteinyl Amide Inhibitors: A Novel Approach to Controlling Cancers with Hyperactive Growth Signaling.Current medicinal chemistry · 2021Article
- HER2 Overexpression and Mismatch Repair Deficiency are Correlated with Malignancy in Colorectal Cancer.Cancer management and research · 2021Article
- Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer.Virchows Archiv : an international journal of pathology · 2020Article
- Article
- Significance of HER2 protein expression andWorld journal of gastrointestinal oncology · 2019Article
- Metastatic colonic and gastric polyps from breast cancer resembling hyperplastic polyps.Surgical case reports · 2018Article
- Frequency of Her2/neu expression in colorectal adenocarcinoma: a study from developing South Asian Country.BMC cancer · 2016Article
- HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.World journal of gastroenterology · 2016Review
- Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.Oncology letters · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHER-2/neu and VEGF expression is correlated with disease behaviors in various cancers. However, evidence for their expression in colon cancer is rather contradictory both for the protein expression status and prognostic value. HER-2/neu is found to participate in VEGF regulation, and has known correlation with VEGF expression in some tumors. In this study, we investigated HER-2/neu and VEGF expression in Chinese colon patients and explored whether there was any correlation between their expression patterns.
methodsHER-2/neu and VEGF were investigated immunohistochemically using tumor samples obtained from 317 colon cancer patients with all tumor stages. Correlation of the degree of staining with clinicopathological parameters and survival was investigated.
resultsPositive expression rates of HER-2/neu and VEGF in colon cancer were 15.5% and 55.5% respectively. HER-2/neu expression was significantly correlated with tumor size and distant metastases (P < 0.05), but was not an independent prognostic marker of survival (P > 0.05). Expression of VEGF was significantly correlated with tumor size, tumor stage, lymph node metastases, and distant metastases (P < 0.05). The 5-year survival rate in patients with negative and positive VEGF expression was 70.2% and 61.9% respectively; the difference was not statistically significant (P = 0.146). No correlation between HER-2/neu and VEGF expression was detected (P = 0.151).
conclusionsHER-2/neu and VEGF are not important prognostic markers of colon cancer. The present results do not support any association between HER2/neu and VEGF expression in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.